This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RYZB RayzeBio (RYZB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesTrendsBuy This Stock About RayzeBio Stock (NASDAQ:RYZB) Get RayzeBio alerts:Sign Up Key Stats Today's Range$62.49▼$62.4950-Day Range$62.27▼$62.4952-Week Range$17.95▼$62.51VolumeN/AAverage Volume553,592 shsMarket Capitalization$3.74 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company. Read More Receive RYZB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RayzeBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RYZB Stock News HeadlinesEsports Entertainment (OTC:GMBL) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comNextPlay Technologies (OTC:NXTP) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.July 1 at 1:00 AM | Stansberry Research (Ad)LeddarTech Holdings (NASDAQ:LDTC) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comGetting In on This "Macro-Trend"May 10, 2024 | nasdaq.comAndreas Halvorsen's Firm Sells Out of RayzeBio IncFebruary 28, 2024 | finance.yahoo.comRYZB Aug 2024 35.000 putFebruary 27, 2024 | finance.yahoo.comRYZB May 2024 55.000 putFebruary 27, 2024 | finance.yahoo.comSee More Headlines RYZB Stock Analysis - Frequently Asked Questions When did RayzeBio IPO? RayzeBio (RYZB) raised $294 million in an initial public offering (IPO) on Friday, September 15th 2023. The company issued 17,277,600 shares at $16.00-$18.00 per share. What other stocks do shareholders of RayzeBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that RayzeBio investors own include Apogee Therapeutics (APGE), Broadcom (AVGO), Citigroup (C), Citizens Financial Group (CFG), Cisco Systems (CSCO), Fifth Third Bancorp (FITB) and Intel (INTC). Company Calendar Today7/01/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:RYZB CIK1825367 Webrayzebio.com Phone619-937-2754FaxN/AEmployees88Year Founded2020Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio31.85 Quick Ratio31.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares59,920,000Free FloatN/AMarket Cap$3.74 billion OptionableNo Data BetaN/A Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:RYZB) was last updated on 7/1/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RayzeBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RayzeBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
